Avelas Biosciences
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
11099 N Torrey Pines Rd Ste 290, La Joll...Phone Number
(858) 750-4700Website
www.avelasbio.comRevenue
$20.7 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Avelas Biosciences
Avelas Biosciences is a biotechnology company focused on developing pegloprastide (AVB-620), a novel drug-device combination product for use during cancer surgery. Pegloprastide is designed to improve surgery by detecting cancer in real time and has the potential to become part of standard-of-care treatment for a variety of cancer surgeries. Avelas was founded on technology from Roger Y. Tsien, Ph.D., co-winner of the Nobel Prize in Chemistry 2008.Explore more
Avelas Biosciences Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Avelas Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Avelas Biosciences
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Avelas Biosciences had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Avelas Biosciences recently announced quarterly report
Funding: Get notified immidiatlly once Avelas Biosciences has new funding data
Check if Avelas Biosciences has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Avelas Biosciences launches new products
Avelas Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Avelas Biosciences is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Avelas Biosciences as Masked Content
Find more new buyers
Compare Similar Companies to Avelas Biosciences
Compare insights from companies similar to Avelas Biosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Avelas Biosciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Avelas Biosciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Avelas Biosciences.
Avelas Biosciences financials insights
Gather financial insights about Avelas Biosciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2012
Series A
$7.7M
2014
Series B
$7.4M
2016
Series C
$20M
Avelas Biosciences Tech Stack
A closer look at the technologies used by Avelas Biosciences
See more technologies
Avelas Biosciences News & Media
Avelas Receives FDA Breakthrough Therapy Designation for Pegloprastide (AVB-620) for Use During Breast Cancer Surgery
SAN DIEGO--(BUSINESS WIRE)-- #breastcancer--Avelas Receives FDA Breakthrough Therapy Designation for Pegloprastide (AVB-620) for Use During Breast Cancer SurgeryAvelas Announces Top-Line Data Showing Pegloprastide (AVB-620) Can Significantly Improve Cancer Detection in Real Time During Breast Cancer Surgery
SAN DIEGO--(BUSINESS WIRE)-- #breastcancer--Top-line data showed the planned re-excision rate for patients who underwent breast cancer surgery with pegloprastide was 6% (vs typical rate 20-40%).Avelas Biosciences to Present at 2018 Cantor Global Healthcare Conference
SAN DIEGO, Sept. 26, 2018 /PRNewswire/ -- Avelas Biosciences, Inc., a clinical stage oncology-focused platform technology company that is developing products to advance a new standard-of-care for cancer surgery and therapeutic intervention, today announced that Ms. Kyri Van Hoose, Head of ...Avelas Biosciences Initiates Period 2 of Phase 2 Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery
SAN DIEGO, Aug. 2, 2018 /PRNewswire/ -- Avelas Biosciences, Inc., a clinical stage oncology-focused company that is developing products to advance a new standard-of-care for cancer surgery and therapeutic intervention, today announced that the first patient has been dosed in Period 2 of...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Avelas Biosciences
Sign Up For FreeTo access detailed company insights
Avelas Biosciences is a biotechnology company focused on developing pegloprastide (AVB-620), a novel drug-device combination product for use during cancer surgery. Pegloprastide is designed to improve surgery by detecting cancer in real time and has the potential to become part of standard-of-care treatment for a variety of cancer surgeries. Avelas... Read More
